While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.
The experimental drug called AMX0035 will be considered by the U.S. Food and Drug Administration on Sept. 29. and, if approved, would give patients with the degenerative disease hope for slowing the progression.
At Holy Cross Health and NSU Health Neuroscience Institute, ALS specialists began enrolling participants in a major clinical trial for the drug for amyotrophic lateral sclerosis in July. The medication is free for those in the trial, and doctors monitor patient responses.
